Breast implant-associated anaplastic large-cell lymphoma: Long-term follow-up of 60 patients

Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince, Rashmi Kanagal-Shamanna, Daphne De Jong, Luis E. Fayad, Mitual B. Amin, Nisreen Haideri, Govind Bhagat, Glen S. Brooks, David A. Shifrin, Dennis P. O'Malley, Chan Y. Cheah, Carlos E. Bacchi, Gabriela Gualco, Shiyong Li, John A. Keech, Ephram P. Hochberg, Matthew J. Carty, Summer E. HansonEid Mustafa, Steven Sanchez, John T. Manning, Zijun Y. Xu-Monette, Alonso R. Miranda, Patricia Fox, Roland L. Bassett, Jorge J. Castillo, Brady E. Beltran, Jan Paul De Boer, Zaher Chakhachiro, Dongjiu Ye, Douglas Clark, Ken H. Young, L. Jeffrey Medeiros

Research output: Contribution to journalArticlepeer-review

256 Citations (Scopus)


Purpose: Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an effusion-associated fibrous capsule surrounding an implant. Less frequently, it presents as a mass. The natural history of this disease and long-term outcomes are unknown. Patients and Methods: We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up. Results: The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively). Conclusion: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalJournal of Clinical Oncology
Issue number2
Publication statusPublished - Jan 2014
Externally publishedYes


Dive into the research topics of 'Breast implant-associated anaplastic large-cell lymphoma: Long-term follow-up of 60 patients'. Together they form a unique fingerprint.

Cite this